Navigation Links
Mylan Inc., NATCO Pharma Ltd. To Collaborate on Worldwide Marketing and Distribution of Generic Copaxone(R)
Date:6/10/2008

PITTSBURGH, June 10 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that it has signed a license and supply agreement with NATCO Pharma Ltd. (NATCO) for NATCO's glatiramer acetate pre-filled syringes, a generic version of Teva's Copaxone(R), which is used to treat multiple sclerosis. The agreement grants Mylan exclusive distribution rights in the United States and all major markets in Europe, Australia, New Zealand, Japan and Canada and includes an option to expand into additional territories.

NATCO has commercialized successfully its glatiramer acetate product in India and the Ukraine. Teva has reported that worldwide sales of Copaxone were more than $1.7 billion in 2007.

"We are extremely pleased to be collaborating with NATCO to market and distribute this critically important product virtually worldwide," said Robert J. Coury, Mylan vice chairman and CEO. "We've worked closely with NATCO over the past several months, and we're excited to have completed this agreement. During that time, we have been impressed with the company's long-term vision and outstanding technical capabilities, which are clearly reflected in NATCO's ability to develop a complex product such as generic Copaxone. We plan to work closely with all relevant regulatory agencies in the United States and internationally -- and leverage Mylan's considerable global expertise in regulatory applications -- to bring the therapeutic and economic benefits of this product to the widest possible patient-base."

"We had spoken with several potential partners since we launched glatiramer as a generic in India last year," said NATCO Chairman and Managing Director Chowadary V. Nannapaneni. "After an extensive review, we believe that no company is better positioned than Mylan to help us unlock the extraordinary value of this product in the United States and around the world. We are truly excited about our collaboration."

Mylan Inc., with a presence in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies

NATCO Pharma Limited, based in Hyderabad, India, is ranked among the fastest growing pharmaceutical companies in the country. It manufactures branded and generic dosage forms, bulk actives and intermediates for Indian and international markets. During its 24-year history, NATCO has gained a reputation for innovative product development, high-quality manufacturing capabilities and strong financial growth.

Copaxone(R) is a registered trademark of Teva Pharmaceutical Industries Ltd.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Announces Final FDA Approval for Zaleplon Capsules
2. Mylan Inc. Acquires Central Eastern European Generics Businesses of Merck KGaA
3. Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets
4. Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
5. Mylan Declares Quarterly Preferred Stock Dividend
6. Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs
7. Mylan Announces Final FDA Approval for Trandolapril Tablets
8. Mylan Announces Final FDA Approval for Felodipine Extended-Release Tablets, USP
9. Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
10. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
11. Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec. 31, 2007, to 5 p.m. ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 23, 2017 , ... United Nations Foundation President ... the Mexico City Policy, also known as the Global Gag Rule, last enacted ... prohibits foreign non-governmental organizations from receiving any U.S. foreign assistance for family planning ...
(Date:1/24/2017)... ... 23, 2017 , ... Texas Home Health, an AccentCare, Inc. ... care service companies: Padre Home Health in Corpus Christi, Texas, and Royalty Personal ... regarded in their respective markets, these two agencies align with Texas Home Health’s ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... ... men who support them, Dr. Carol Francis, Psychologist in the South Bay ... pay, humane respectful governing for all people and by all people shines as ...
(Date:1/24/2017)... ... , ... The National Council of Alcoholism and Drug Dependence ( NCADD ), ... communities to designate the last full week of January as National Drug and Alcohol ... Myths.” As a community, we can advocate for effective treatment, but also especially ...
(Date:1/23/2017)... ... ... PKF O’Connor Davies , LLP, the nation’s 26th largest accounting and ... will participate in the 40th Annual "Empire State Building Run Up" on Feb. 1 ... a vertical distance equal to about a fifth of a mile, to reach the ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... SAN FRANCISCO , January 23, 2017 The global  ... USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated ... and psychotherapies has resulted in the declining demand for antidepressants in the recent ... ... Grand View Research Logo ...
(Date:1/23/2017)... Januar 2017  ResMed (NYSE: RMD ), ... Medical ( Winter Haven, Florida ) gaben ... die Beilegung aller globalen Rechtsstreitigkeiten zwischen den Parteien geeinigt ... ihrer bestehenden Produkte im Tausch gegen Lizenzgebühren an ResMed ... leisten, um das in Florida ...
(Date:1/23/2017)... , Jan 23, 2017 NeuroVive Pharmaceutical ... has signed a preclinical collaboration agreement with the Children,s Hospital ... J. Falk , M.D., a US key opinion leader in ... ... will evaluate compounds from NeuroVive,s research program, NVP015, in certain ...
Breaking Medicine Technology: